Transmit Security Expands in Europe
Transmit Security, a leading provider of customer identity and access management (CIAM) SaaS solutions, today announced its significant expansion and growth in Europe to address rapidly growing demand for passwordless customer authentication and other solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511006152/en/
In January, the company hired Dr. Thore Rabe as the new Vice President and General Manager for Europe, Middle East and Africa (EMEA). Rabe oversees all aspects of Transmit Security’s business in EMEA. Thore has over 20 years leading European divisions at Qumulo, Dell EMC, NetApp, Fujitsu Siemens, and Computer Associates and earned his doctorate in Economic Sciences.
“Our expansion comes at a critical time, not just for us, but for the market here in Europe. With the increase in account takeover fraud, we’re seeing substantial demand for passwordless customer authentication that doesn’t require a specialized app or token,” says Rabe. “The pandemic-fuelled growth in mobile app usage along with the brick-and-mortar return of consumers means businesses need stronger, easy-to-use authentication that works across all of their channels. Our customers know they have to serve their consumers digitally, no matter where they are or what devices they use.”
Consumers around the world report that they prefer better security and smooth customer experience; businesses are increasingly turning to passwordless authentication as the solution. With the growing demand in Europe, Transmit Security has invested heavily in the region, more than doubling its Europe-based employees and growing by 255% across EMEA, including its corporate headquarters in Tel Aviv.
Transmit Security’s customers in EMEA include HSBC, UBS, Telepass S.p.A., Santander, MetroBank and NN Insurance, and dozens of other regional and global companies. Transmit Security helps its customers in the region address many customer identity challenges, including improving customer experience across their digital channels while strengthening authentication against phishing and other threats. Altogether, the company’s customers in EMEA represent over €330 billion in annual revenues.
Transmit Security is a Platinum Sponsor at the Gartner Identity & Access Management Summit on May 12-13 in London (booth 202). They will be presenting, “Fortify Security and Remove Customer Barriers with Passwordless” on Friday at 2:45pm.
About Transmit Security
Transmit Security is on a mission to revolutionize consumer identity and access management by reimagining customer experience (CX) and eliminating account takeover fraud and similar risks. CX-focused, cybersecurity-conscious businesses rely on Transmit Security to deliver innovative, passwordless digital identity journeys for their consumers across all channels and devices. Transmit Security’s customers are responsible for more than $1.3 trillion in annual commerce and include many of the largest banks, insurers, and retailers, along with many other leading brands.
For more information, please visit www.transmitsecurity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511006152/en/
Contact information
Press
Todd Tucker
media@transmitsecurity.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
